Metronomic chemotherapy is now, finally, in clinical use. After 20 years of preclinical development and clinical trials, the emerging data will be of paramount importance in allowing us to assess the impact of metronomic chemotherapy on different tumor types. Indeed, it is likely that the next decade will see a major reassessment of the possible applications of metronomic chemotherapy, both alone and in combination with new therapeutic approaches such as immunotherapies, for the management of cancer. Moreover, the results of clinical trials will likely profoundly affect the direction of the laboratory efforts that are going on in parallel and aiming to improve the personalization of this therapeutic strategy. This Special Issue is our attempt to cover the past and present clinical results that have brought us to this pivotal moment and will form the basis of future clinical developments. Scientists and clinicians caring for cancer patients are well aware of the challenges in dealing with this particular therapeutic approach; one such challenge is obtaining improvements in patient survival without significant toxicity. This edition includes clinical research on chemotherapy and ongoing controversies related to metronomic chemotherapy.
外文書商品之書封,為出版社提供之樣本。實際出貨商品,以出版社所提供之現有版本為主。部份書籍,因出版社供應狀況特殊,匯率將依實際狀況做調整。
無庫存之商品,在您完成訂單程序之後,將以空運的方式為你下單調貨。為了縮短等待的時間,建議您將外文書與其他商品分開下單,以獲得最快的取貨速度,平均調貨時間為1~2個月。
為了保護您的權益,「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。
若要辦理退貨,請在商品鑑賞期內寄回,且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。